Depression of macrophage function by a factor produced by neoplasms: a merchanism for abrogation of immune surveillance.

Marilyn C. Pike(Bethesda Hospital), Ralph Snyderman(Duke University)

PubMed

October 1, 1976

Cited by 155

Related Papers

Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2

|Circulation|2002|652

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

|Annals of the Rheumatic Diseases|2013|340

Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure

|Kidney International|1999|305

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial

|Arthritis & Rheumatology|2022|261

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials

|Arthritis & Rheumatology|2016|237